Axsome Therapeut (AXSM) Stock News

Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on CNS disorders, has announced its participation in six major investor conferences during September 2025. The company will engage in fireside chats at the Wells Fargo Healthcare Conference (Sept 3), Cantor Global Healthcare Conference (Sept 4), Morgan Stanley Global Healthcare Conference (Sept 8), Baird Global Healthcare Conference (Sept 10), and TD Cowen Novel Mechanisms Summit (Sept 17), followed by investor meetings at the Deutsche Bank Virtual BioPharm Corporate Day (Sept 18).

Live webcasts will be available for four of the presentations and can be accessed through Axsome's website, with replays available for approximately 30 days after each event.

Axsome Therapeutics (NASDAQ:AXSM) reported strong Q2 2025 financial results, with total net product revenue of $150.0 million, up 72% year-over-year. The company's flagship product AUVELITY achieved sales of $119.6 million (+84% YoY), while SUNOSI revenue reached $30.0 million (+35% YoY). The newly launched SYMBRAVO contributed $0.4 million since its June 10th launch.

Key financial metrics include a net loss of $48.0 million ($0.97 per share) and cash reserves of $303.0 million. The company expanded AUVELITY's market access by 28 million new covered lives and signed its first GPO contract for SYMBRAVO. Axsome remains on track for upcoming regulatory submissions, including an sNDA for AXS-05 in Alzheimer's disease agitation (Q3 2025) and an NDA for AXS-12 in narcolepsy (Q4 2025).

[ "Total net product revenue grew 72% YoY to $150.0 million", "AUVELITY sales increased 84% YoY to $119.6 million", "SUNOSI revenue grew 35% YoY to $30.0 million", "AUVELITY market access expanded by 28 million new covered lives", "Strong cash position of $303.0 million sufficient to fund operations to cash flow positivity", "Net loss improved from $79.3 million in Q2 2024 to $48.0 million in Q2 2025" ]

Axsome Therapeutics (NASDAQ: AXSM) is hosting its Frontiers in Brain Health R&D Day to showcase its extensive CNS pipeline. The event features presentations from six leading expert clinicians who will discuss various neurological and psychiatric conditions including Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation.

Key speakers include renowned experts who will present clinical data and trial results for various drug candidates including AXS-14 for fibromyalgia, AXS-05 for Alzheimer's disease agitation, solriamfetol for ADHD and MDD, SYMBRAVO for migraine, and AXS-12 for narcolepsy. The event will be accessible via webcast for institutional investors and sell-side analysts.

Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, announced that CEO Herriot Tabuteau and the management team will ring the NASDAQ opening bell on July 21, 2025. The ceremony coincides with their Frontiers in Brain Health R&D Day event.

The event highlights Axsome's progress in developing late-stage CNS product candidates and celebrates the recent U.S. launch of SYMBRAVO®. The company aims to transform clinical practice in brain health through its portfolio of marketed medicines and investigational treatments for CNS conditions. The bell ringing ceremony will be held at the Nasdaq MarketSite in Times Square, New York, starting at 9:20 a.m. ET.

Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, will release its Q2 2025 financial results on Monday, August 4, 2025, before U.S. markets open.

The company will host a conference call at 8:00 AM ET to discuss the results and provide business updates. Investors can join via phone or watch the webcast on Axsome's website, where a replay will be available for approximately 30 days.

Axsome Therapeutics (NASDAQ:AXSM), a biopharmaceutical company focused on central nervous system (CNS) disorders, will host its Frontiers in Brain Health R&D Day on July 21, 2025 at 11:00 a.m. ET in New York City.

The event will showcase Axsome's late-stage CNS pipeline, featuring presentations from physician key opinion leaders discussing current neurology and psychiatry indications. The company's management team will provide detailed insights into their clinical development programs, followed by a Q&A session.

The R&D Day is specifically designed for institutional investors and sell-side analysts, with limited in-person attendance available through RSVP. A live webcast will be accessible to the public through the company's website.

Axsome Therapeutics (NASDAQ: AXSM) is joining the Alzheimer's disease advocacy community during Alzheimer's & Brain Awareness Month to highlight the growing impact of Alzheimer's disease in the US. The company emphasizes that over 7 million Americans now live with Alzheimer's, with projections showing an increase to 14 million by 2060. Research indicates that up to 45% of dementia cases may be linked to modifiable risk factors. The disease has risen from the 12th most burdensome disease in 1990 to the sixth in 2016 in terms of disability-adjusted life years. Axsome is collaborating with advocacy and patient communities to raise awareness and share resources, while also participating in scientific and medical conferences throughout the year.

Axsome Therapeutics (NASDAQ: AXSM) will present clinical data for SYMBRAVO® (meloxicam and rizatriptan) at the 67th Annual Scientific Meeting of the American Headache Society (AHS) from June 19-22, 2025, in Minneapolis. The presentations will showcase three key studies: the INTERCEPT trial analyzing SYMBRAVO's efficacy based on baseline migraine-associated disability, the MOVEMENT trial examining long-term effects on headache burden and quality of life, and the EMERGE trial investigating efficacy in patients with inadequate response to oral CGRP inhibitors. Notable researchers including Dr. Stewart Tepper from Dartmouth and Dr. Richard B. Lipton from Albert Einstein College of Medicine will lead the presentations.

Axsome Therapeutics (NASDAQ: AXSM) is supporting Migraine and Headache Awareness Month in June 2025 in collaboration with the Association of Migraine Disorders. The company is backing over 12 Miles for Migraine Run, Walk or Relax events nationwide and providing educational resources for migraine patients and their families. Migraine, affecting approximately 40 million Americans, is the second leading cause of disability worldwide. The condition causes debilitating headaches with symptoms including nausea and sensitivity to light and sound. Axsome is sharing resources from major migraine advocacy organizations, including the American Migraine Foundation's doctor finder, AMD's educational videos, CHAMP's financial assistance guides, and the National Headache Foundation's podcast.